Please login to the form below

Not currently logged in
Email:
Password:

Czech biotech Sotio selects Chiltern International

UK CRO will work on late-stage trials for its prostate cancer therapy

UK headquartered contract research organisation (CRO) Chiltern International has been appointed by Czech biotech Sotio to carry out phase III clinical trials.

Under the agreement, the CRO will provide full-service management of the phase III trials, entitled Viable, which will involve 126 treatments for 750 prostate cancer patients from across Europe.

The trials will assist the biotech company's development of Active Cellular Immunotherapy (ACI), which focuses on cancer and autoimmune disease treatments - specifically, therapies using an immunotherapy platform based activated dendritic cells.

Chiltern will also be responsible for processing the data obtained during the clinical evaluation.

"I am very pleased that we have been selected to manage this high profile trial," said Chiltern CEO Dr Jim Esinhart.

"I believe it underscores the strengths and expertise of our global oncology therapeutic area team. We look forward to working in close partnership with Sotio deliver a quality outcome."

Viable will be a global clinical trial, tracking a total of 1,170 prostate cancer patients from Europe and the US.

19th March 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics